Quarterly Result3 Aug 2026, 04:11 pm
GSK India Q1FY27 PAT Grows 24% to ₹253 Cr on 15% Revenue Rise
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported strong financial results for the first quarter ended June 30, 2026. Revenue increased by 15% year-on-year to INR 924 crores, while Profit After Tax (PAT) surged by 24% to INR 253 crores. EBITDA margins stood at 32%. The company highlighted growth across its General Medicines, Respiratory, and Vaccines portfolios, with key brands like Augmentin and Nucala showing strong performance. The Oncology business also saw significant growth. GSK India is preparing for upcoming launches, including Blenrep and Arexvy, and has strengthened its supply chain resilience.
Key Highlights
- Q1FY27 Revenue up 15% YoY to ₹924 Cr.
- PAT increased 24% YoY to ₹253 Cr.
- EBITDA margins reported at 32%.
- Strong performance in General Medicines, Vaccines, and Oncology.
- Upcoming launches include Blenrep and Arexvy.
Price Impact
More from GLAXO